Effects of Ligustilide on Tumor Growth and Immune Function in Institute of Cancer Research Mice
AbstractPurpose: To investigate the immunomodulatory and antitumor activities of ligustilide (LIG) extracted from Angelica sinensis in mice.
Methods: Normal and tumor-bearing Institute of Cancer Research (ICR) mice were treated p.o. with LIG (5, 20 and 80 mg/kg/day) for 7 days. In normal ICR mice, phagocytosis of peritoneal macrophages and serum hemolysin concentration were assessed by chicken red blood cell ingestion test and quantitative hemolysis of sheep red blood cells assay, respectively. Lymphocyte proliferation was determined by 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide (MTT) method. Both cytotoxic T lymphocyte (CTL) and natural killer (NK) cell activities were evaluated by lactate-dehydrogenaserelease assay. H22 ascites tumor cells were inoculated subcutaneously into ICR mice, followed by the determination of antitumor activity of LIG in the H22-bearing mice.
Results: LIG significantly increased thymus and spleen index, macrophage phagocytosis, serum hemolysin concentration, spleen lymphocyte proliferation and CTL and NK cell activities in normal ICR mice, but inhibited the growth of transplantable H22 hepatoma. The effect was dose-related but not in a linear fashion. A dose of 20 mg/kg dose was more effective than 5 and 80 mg/kg doses.
Conclusion: These results suggest that LIG at 20 mg/kg has a highly boosted the immune system and tumor inhibition.
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.